Cantor Fitzgerald analyst Louise Chen maintained a Hold rating on Mylan Inc (MYL) yesterday and set a price target of $41. The company’s shares closed yesterday at $33.91.
Chen commented:
“We rate MYL as 12-month price target of $41. We like the company, and there are a lot of potentially positive catalysts coming up. That said, the risk reward is already reflected in the stock’s valuation, in our view. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to calculate our 12- month price target of $41.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 10.2% and a 40.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Amneal Pharmaceuticals Inc.
Mylan Inc has an analyst consensus of Moderate Buy, with a price target consensus of $41.92, which is a 23.6% upside from current levels. In a report issued on November 6, Morgan Stanley also maintained a Hold rating on the stock with a $39 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $47.82 and a one-year low of $30.33. Currently, Mylan Inc has an average volume of 4.74M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe, Rest of World, and Corporate or Other.
